Ask AI
ProCE Banner Activity

Precision in Practice: Examining the Clinical Implications of Emerging mCRPC Therapies on the Horizon

Slideset

Download these slides from a recent live webinar on emerging therapies for metastatic castration-resistance prostate cancer, including PARP inhibitors, radioligands, and EZH2 and CYP11 inhibitors, based on evidence from key clinical trials.

Released: January 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Novartis Pharmaceuticals Corporation.

AstraZeneca

Novartis Pharmaceuticals Corporation

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurses, pharmacists, and other community and specialist healthcare professionals involved in the management of patients with castration-resistant prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate colleagues and patients on the mechanism of action and rationale for novel therapies under investigation in mCRPC

  • Evaluate new data on novel agents and therapeutic approaches for patients with mCRPC

  • Identify patients with mCRPC who may be eligible for ongoing clinical trials of novel therapies

  • Implement strategies to support equitable access to clinical trials of novel therapies in Black and other underserved patient populations with mCRPC